• Molecular NameZalcitabine
  • SynonymDDC; DDCYD; Dideoxycytidine
  • Weight211.221
  • Drugbank_IDDB00943
  • ACS_NO7481-89-2
  • Show 3D model
  • LogP (experiment)-1.3
  • LogP (predicted, AB/LogP v2.0)-1.11
  • pkaN/A
  • LogD (pH=7, predicted)-1.11
  • Solubility (experiment)76.7 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-1.02
  • LogSw (predicted, AB/LogsW2.0)50.22
  • Sw (mg/ml) (predicted, ACD/Labs)20.15
  • No.of HBond Donors3
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds2
  • TPSA88.15
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA nucleoside analog reverse transcriptase inhibitor (NARTI)
  • Absorption_value85.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability88.0
  • Protein binding4.0
  • Volume of distribution (VD)Adults: 0.54 L/kg; children: 9.3 L/m3.
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic
  • Half lifeAdults: 1 to 3 h; children: 0.8 h. Prolonged in patients with renal impairment, up to 8.5 h (with creatinine clearance < 55 mL/min).
  • ExcretionRenal (circa 80%)
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityAcute overdose: Inadvertent pediatric overdoses have occurred with doses up to 1.5 mg/kg zalcitabine. Chronic overdose: in an initial dose-finding study in which zalcitabine was administered at doses 25 times (0.25 mg/kg every 8 hours) the currently recommended dose, one patient discontinued zalcitabine after 1???? weeks of treatment subsequent to the development of a rash and fever.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A